ABSTRACT Esophageal Crohn’s disease (CD) is poorly studied despite being a significant predictor of intestinal CD progression and recurrence. Management has historically focused on steroids and acid suppression, with some success from immunosuppressants and biologics like antitumor necrosis factor-α agents. However, no specific guidelines exist for treating esophageal CD. Risankizumab, a human monoclonal antibody of interleukin-23, has shown promise in treating both induction and maintenance of remission in CD. This case series represents the first reported use of risankizumab in esophageal CD. Despite the absence of guidelines for esophageal CD management, these cases suggest that risankizumab may offer a valuable treatment option and should be strongly considered for managing esophageal CD.
Hallcox et al. (Fri,) studied this question.